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Background 
Bibliography 
Conclusion and Perspectives:  We have identified a novel chemical scaffold, that demonstrates cytotoxic activity in 
vitro in a range of human cell lines, including MCF7 and SKBR3 (Breast), DU145 (Prostate) and A549 (Lung). Our 
working hypothesis has been that hybridization of several bioactive fragments results in synergized bioactivity 
(Figure 2 and 3). The results demonstrate the validity of this hypothesis, showing that the nature and position of 
substitution together with stereo-isomeric specificity results in significant increases in bioactivity: e.g. coupling of 
indan-1-one (IC50 100 micromolar in SKBR3, A549, MCF7 and IC50 40.88 micromolar in DUI45) with fragment A 
(IC50 100 micromolar in SKBR3 and MCF7; and IC50 46.4 micromolar in A549, and IC50 33.54 micromolar in 
DU145) yields a novel chemical scaffold with (IC50 1.04 micromolar in SKBR3, 14.9 in A549, 32.1 in DUI145 
(Prostate) and 30.5 in MCF7. One hybrid 14b2t compares well with Tamoxifen across the cell lines. Several hybrids 
are more potent in the SKBR3 cell line. Future chemical synthesis: We are working to couple indanone nuclei with 
new fragments we have prepared,  that display nanomolar activity across the four cell lines, to generate what we 
believe will be derivatives with significant nanomolar dual activities. Future bioactivity evaluation: Initial studies 
also support the tubulin binding effects of scaffolds. This activity will be further evaluated in collaboration with the 
CNRS , Gif-Sur=Yvette in March. In addition  P-glycoprotein (P-gp) modulating activity will be evaluated. A series 
of indebt in vitro anticancer assessments and in vivo and in vitro antiinflammatory studies will be carried out over the 
next six months, to establish MOA and selectivity of these scaffolds. 
 
Drug discovery: Novel indane scaffolds                        
with anticancer activity 
. 
The indane scaffold is of key importance in the natural world. It occurs in a range of biologically active 
natural products. The natural structures range from simple indanes and indanones with antibacterial 
activity e.g. indanone 1 isolated from the cyanobacterium Nostoc 1 to the pterosin family of fern and 
fungal metabolites e.g. 2, which show cytotoxicity toward the Human leukaemia HL-60 cell line 2, 3, to 
oligomers of resveratrol (3,5,4‘-trihydroxystilbene) e.g. the indane Pauciflorol F isolated from the 
Dipterocarpaceae.4 The therapeutic potential of indanes becomes more evident in the area of medicinal 
chemistry where this scaffold is incorporated into structures that demonstrate therapeutic properties e.g. 
the indanone Sulindac (Clinoril™; Merck), a non-steroidal anti-inflammatory that has recently 
demonstrated anti-proliferative and apoptotic effects.5,6 More recently the tubulin polymerisation 
inhibitor Indanocine (NIH) has been receiving attention.7 During the course of our research on indane 
monomers and dimers, we have noted that the potential of novel indane scaffolds for the treatment of 
inflammatory disease and cancer has not been fully exploited. Inflammatory disease is responsible for, 
or implicated in, a wide range of conditions including, but not limited to, Rheumatoid Arthritis, 
Cardiovascular Disease, Multiple Sclerosis, inflammatory bowel disease (IBD) and Psoriasis. It is also 
well established that inflammation plays a significant role in the development of cancer.8  The aim of 
this research project is to combine, experience led and evidence based, theories with our knowledge of 
small molecule drug development to generate novel hybrid scaffolds with therapeutic potential for the 
treatment of cancer and inflammatory disease. The second fragment of interest, in this study comes 
from the naturally occurring benzophenones.9 This class of molecules features widely in plants used as 
anti-tumour agents in Traditional Herbal Medicinal systems. A range of bioactivities has been 
established for members of this chemical class, including tubulin binding and P-glycoprotein (P-gp) 
modulating activity, the prototypical efflux transporter, implicated in multidrug resistance (MDR).10 
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Results and Discussion 
Methods:  
Synthesis and specific compounds: Will not be discussed at this point. Cell Culture: All the cell lines were 
maintained in a humid chamber at 37 ºC and 5% CO2 atmosphere. SKBR3  (ATCC HTB-30), MCF7 (ATCC HTB-
22), and DU145(ATCC HTB-81) cells were cultured in RPMI-1640 Medium containing 10% fetal bovine serum (FBS) 
and 1% L-Glutamine. A549 (ATCC CCL-185) lung carcinoma cells were grown in Dulbecco′s Modified Eagle′s 
Medium supplemented with 5% FBS. Acid Phosphatase assay: After 5 days of incubation of cells with the drugs, the 
medium was removed and each well was washed with 100 μL of PBS. Then, 100 μL of freshly prepared phosphatase 
substrate (10 mM p-nitrophenol phosphate, Sigma) in 0.1 M sodium acetate (Sigma), 0.1 % triton X-100 pH5.5 (BDH) 
was added to each well. The plates were wrapped in tin foil and incubated in the dark at 37º C for 1 hour. The reaction 
was stopped by the addition of 50 μL of NaOH 1 M to each well and measuring was obtained in a dual beam plate 
reader at 405 nm with a reference wavelength of 620 nm. 
Figure 3: Cytotoxicity of lead hybrids compared with Tamoxifen 
A novel scaffold designed around an indane nucleus was identified as 
the chemical target in this study (Figure 1). The scaffold was 
synthesised by combining a series of small chemical fragments using a 
range of spacer molecules. A second fragment incorporated into the 
molecule is centered on the small naturally occurring bioactive 
benzophenone moiety, which depending on substitution pattern 
demonstrates a variety of biological properties. Initial studies have led 
to the development of a synthetic approach that has thus far yielded 
eight final products with the desired final chemical scaffold. All 
products and intermediates have been characterized spectroscopically.  
The cytotoxicity of the starting fragments was evaluated using the Acid 
Phosphatase assay, in a series of in vitro cancer cell lines: MCF7 and 
SKBR3 (Breast), DUI145 (Prostate) and A549 (Lung). The individual 
fragments displayed low levels of cytotoxicity (Table 1) in A549, 
MCF7 and SKBR3 cell lines, but do have low micro-molar activity in 
the DU145. Some fragments with significant cytotoxicity (in red, Table 
1) have been prepared and await coupling. Coupling of the main 
molecular fragments and spacers gave rise to a series of compounds 
with a novel chemical scaffold. These molecules displayed significant 
increases in IC50 values in the cell lines under investigation, relative to 
their component fragments (Figure 2). Initial and ongoing studies have 
demonstrated inhibition of tubulin binding at micro molar levels.  
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Figure 1: Target Hybrid Scaffold 
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Cytotoxicity of  composite fragments and first hybrid in four cell lines 
SKBR3
1-IND 4-OCH3-BP 014b2t
0
100
200
300
**
##
IC
5
0
 (

M
)
A549
1-IND 4-OCH3-BP 014b2t
0
100
200
300
***
##
***
IC
5
0
 (

M
)
DU145
1-IND 4-OCH3-BP 014b2t
0
100
200
300
***
###
IC
5
0
 (

M
)
MCF7
1-IND 4-OCH3-BP 014b2t
0
500
1000
***
**
IC
5
0
 (

M
)
Figure 2: Modification of one fragment increased activity of hybrid all cell  lines 
Fragments 
IC50 
MCF7 
M 
SKBR3 
M 
A549 
M 
DU145 
M 
> 100 > 100 > 100 
 
40.88 
> 100 
 
> 100 
 
> 100 
 
28.41 
> 100 
 
> 100 
 
46.42 33.50 
> 100 
 
> 100 
 
56.63 19.74 
> 100 
 
> 100 
 
26.60 24.52 
***8.73 nM 379 nM 29.8 nM 
 
11.7 nM 
 
***35.4 nM 514 nM 17.4 nM 
 
 
6.16 nM 
O
O
O
CH3
O
CH3H3C
O
OCH3H3CO
OCH3
O
H3CO
H3CO
OCH3
OH
Table 1: Cytotoxicity of some fragments before coupling  
to form hybrids  
***Fragments have been synthesised and await coupling. We 
expect significant increases in activity for the final hybrids. 
Cl
O
O
O
OCH3
H3CO
H3CO
OCH3
SKBR3
S
ul
in
da
c
Ta
m
ox
ife
n
00
4
01
1c
01
1t
01
2c
01
2t
01
5
01
4b
2t
01
4b
2c
01
8b
4
01
8b
5
04
6
0
100
200
300
400
500
* **** ***** *** *** *** ***
******
### ### ###
##
#
#
IC
5
0
 (

M
)
A549
S
ul
in
da
c
Ta
m
ox
ife
n
00
4
01
1c
01
1t
01
2c
01
2t
01
5
01
4b
2t
01
4b
2c
01
8b
4
01
8b
5
04
6
0
100
200
300
400
500
*
* * * ** ** **
*
* *
**
ns
**
IC
5
0
 (

M
)
DU145
S
ul
in
da
c
Ta
m
ox
ife
n
00
4
01
1c
01
1t
01
2c
01
2t
01
5
01
4b
2t
01
4b
2c
01
8b
4
01
8b
5
04
6
0
100
200
300
400
500
* * ** ** ** ** ** **
* *
**
ns
IC
5
0
 (

M
)
MCF7
S
ul
in
da
c
Ta
m
ox
ife
n
00
4
01
1c
01
1t
01
2c
01
2t
01
5
01
4b
2t
01
4b
2c
01
8b
4
01
8b
5
04
6
0
100
200
300
400
500
* *
**
IC
5
0
 (

M
)
